tiprankstipranks
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT

Checkpoint Therapeutics (CKPT) Income Statement

1,785 Followers

Checkpoint Therapeutics Income Statement

Last quarter (Q1 2024), Checkpoint Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q1, Checkpoint Therapeutics's net income was $-10.95M. See Checkpoint Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 97.00K$ 103.00K$ 192.00K$ 268.00K$ 1.07M$ 1.71M
Cost of Revenue
------
Gross Profit
$ 97.00K$ 103.00K$ 192.00K$ 268.00K--
Operating Expense
$ 53.02M$ 52.25M$ 58.52M$ 56.99M$ 24.27M$ 26.56M
Operating Income
$ -52.93M$ -52.15M$ -58.33M$ -56.72M$ -23.20M$ -24.85M
Net Non Operating Interest Income Expense
$ 7.65M$ 84.00K$ -4.29M$ 53.00K$ 120.00K$ 136.00K
Other Income Expense
$ -1.61M$ -217.00K$ 4.45M---
Pretax Income
$ -43.66M$ -51.85M$ -62.62M$ -56.67M$ -23.08M$ -24.71M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -43.66M$ -51.85M$ -62.62M$ -56.67M$ -23.08M$ -24.71M
Basic EPS
$ -2.56$ -3.17$ -7.09-$ -0.41$ -0.70
Diluted EPS
$ -2.56$ -3.17$ -7.09$ -7.50$ -0.41$ -0.70
Basic Average Shares
$ 80.37M$ 18.74M$ 8.84M$ 7.60M$ 55.83M$ 35.30M
Diluted Average Shares
$ 80.37M$ 18.74M$ 8.84M$ 7.60M$ 55.83M$ 35.30M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 53.02M$ 52.25M$ 58.52M$ 56.99M$ 24.27M$ 26.56M
Net Income From Continuing And Discontinued Operation
$ -43.66M$ -51.85M$ -62.62M$ -56.67M$ -23.08M$ -24.71M
Normalized Income
$ -28.41M$ -40.96M$ -49.47M-$ -23.08M$ -24.71M
Interest Expense
------
EBIT
$ -43.66M$ -52.15M$ -62.62M$ -56.67M$ -23.20M$ -24.85M
EBITDA
$ -43.66M$ -52.15M$ -62.62M$ -56.67M$ -23.20M$ -24.85M
Currency in USD

Checkpoint Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis